Positive News SentimentPositive NewsNASDAQ:ELTX Elicio Therapeutics (ELTX) Stock Price, News & Analysis $1.77 -0.11 (-5.85%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$1.81 +0.04 (+2.37%) As of 08:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnership About Elicio Therapeutics Stock (NASDAQ:ELTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Elicio Therapeutics alerts:Sign Up Key Stats Today's Range$1.73▼$1.8850-Day Range$1.77▼$3.1952-Week Range$1.71▼$16.00Volume232,018 shsAverage Volume317,115 shsMarket Capitalization$47.95 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingModerate Buy Company Overview Elicio Therapeutics, Inc. is a clinical-stage biotechnology company developing immunotherapies designed to treat cancer by directing immune responses to the lymph nodes, where key immune cells are activated. The company’s technology is based on its Amphiphile platform, which is intended to improve the delivery and activity of therapeutic vaccines and other immune-modulating agents. Elicio’s lead program is ELI-002, an investigational therapeutic cancer vaccine designed to target common KRAS mutations. The program is being evaluated in patients with KRAS-mutated solid tumors, including pancreatic and colorectal cancers. ELI-002 is intended to stimulate T-cell responses against residual disease and tumor cells carrying these mutations. The company is also advancing additional vaccine-based immunotherapies aimed at cancer-associated targets and personalized tumor antigens. Elicio Therapeutics was formerly known as Vedantra Pharmaceuticals and has focused on developing therapies intended to harness the immune system against cancer. Its products remain investigational and are not approved for commercial use.AI Generated. May Contain Errors. Read More Elicio Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreELTX MarketRank™: 3.264163372855 of 5 starsElicio Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 292nd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingElicio Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialElicio Therapeutics has a consensus price target of $15.00, representing about 747.5% upside from its current price of $1.77.Amount of Analyst CoverageElicio Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Elicio Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Elicio Therapeutics are expected to grow in the coming year, from ($1.90) to ($1.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Elicio Therapeutics is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elicio Therapeutics is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElicio Therapeutics has a P/B Ratio of 19.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Elicio Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.03% of the float of Elicio Therapeutics has been sold short.Short Interest Ratio / Days to CoverElicio Therapeutics has a short interest ratio ("days to cover") of 4.12.Change versus previous monthShort interest in Elicio Therapeutics has recently decreased by 6.83%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldElicio Therapeutics does not currently pay a dividend.Dividend GrowthElicio Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News SentimentN/A News SentimentElicio Therapeutics has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Elicio Therapeutics this week, compared to 2 articles on an average week.Search Interest5 people have searched for ELTX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Elicio Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Elicio Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders28.65% of the stock of Elicio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions35.03% of the stock of Elicio Therapeutics is held by institutions.Read more about Elicio Therapeutics' insider trading history. Receive ELTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elicio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELTX Stock News HeadlinesElicio Therapeutics consensus price target lowered by 31.67% to $13.94October 3, 2026 | msn.comB. Riley Adjusts Price Target on Elicio Therapeutics to $8 From $27, Keeps Buy RatingSeptember 25, 2026 | finance.yahoo.comHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling shares or trading options, but simply by holding the fund and letting it pay out cash every Thursday. That works out to a 34% annualized distribution rate, even though the underlying AI stocks pay no dividends themselves. Tim Plaehn, Chief Income Strategist at Investors Alley, breaks down exactly how the fund generates these weekly payouts.October 14 at 1:00 AM | Investors Alley (Ad)Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026September 24, 2026 | globenewswire.comElicio Therapeutics, Inc.(NasdaqCM:ELTX) dropped from S&P Global BMI IndexSeptember 21, 2026 | marketscreener.comMElicio Therapeutics Sets Key 2026 Shareholder Proposal DeadlinesSeptember 14, 2026 | tipranks.comElicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment ConferenceAugust 31, 2026 | globenewswire.comElicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare ConferenceAugust 24, 2026 | globenewswire.comSee More Headlines ELTX Stock Analysis - Frequently Asked Questions How have ELTX shares performed this year? Elicio Therapeutics' stock was trading at $7.96 on January 1st, 2026. Since then, ELTX stock has decreased by 77.8% and is now trading at $1.77. How were Elicio Therapeutics' earnings last quarter? Elicio Therapeutics, Inc. (NASDAQ:ELTX) released its earnings results on Thursday, August, 13th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.11. When did Elicio Therapeutics IPO? Elicio Therapeutics (ELTX) raised $40 million in an IPO on the week of July 26th 2021. The company issued 3,100,000 shares at $12.00-$14.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager. Who are Elicio Therapeutics' major shareholders? Elicio Therapeutics' top institutional shareholders include Shah Capital Management (4.76%). View institutional ownership trends. How do I buy shares of Elicio Therapeutics? Shares of ELTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today10/14/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ELTX's financial health is in the Yellow zone, according to TradeSmith. ELTX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ELTX CIK1555192 Webwww.angion.com Phone415-655-4899FaxN/AEmployeesN/AYear Founded2011Price Target and Rating Average Price Target for Elicio Therapeutics$15.00 High Price Target$23.00 Low Price Target$8.00 Potential Upside/Downside+747.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.57 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,266.43% Return on Assets-139.94% Debt Debt-to-Equity Ratio1.20 Current Ratio2.77 Quick Ratio2.77 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / Book19.67Miscellaneous Outstanding Shares27,090,000Free Float18,752,000Market Cap$47.95 million OptionableNot Optionable Beta1.32 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ELTX) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersThe AI Infrastructure Play Kevin O'Leary Is BackingKevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially...The Tomorrow Investor | SponsoredWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredFox News: Wall Street Can Seize Your RetirementFox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
